IRCT20100228003449N29招募中2 期
Evaluating efficacy and safety of sofosbuvir/ ledipasvir in treatment of COVID-19
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •Patients with highly suspected diagnosis of COVID-19
- •Patients with confirmed diagnosis of COVID-19
- •Patients who are candid for hospitalization
- •Patients who are candid for starting triple-drug combination
排除标准
- •History of drug allergy
研究者
相似试验
Unknown
3 期
Role of anti Hepatitis C drug (Sofosbuvir and Ribavirin)in Liver disease.CTRI/2017/11/010373ATCO PHARMACEUTICALS62
招募中
2 期
Efficacy and safety of Sofosbuvir in the treatment of SARS-CoV-2: An Open Label phase II TrialSARS-CoV-2 ?associated SARI.SARS-CoV-2U07.1IRCT20200328046882N1Shahid Beheshti University of Medical Sciences60
招募中
不适用
Evaluation of the efficacy of sofosbuvir and ledipasvir for Japanese hepatitis C patients: a prospective study in real-life settings.chronic hepatitis CJPRN-UMIN000019468Toranomon Hospital100
招募中
不适用
Evaluation of the efficacy of sofosbuvir/velpatasvir and ribavirin in Japanese hepatitis C patients who failed direct-acting antiviral agents: a prospective study in real life settings.cirrhotic and non cirrhotic patients with hepatitis C virusJPRN-UMIN000035713Toranomon Hospital150
已完成
3 期
Safety and efficacy of sofosbuvir in the moderate COVID19COVID19.Coronavirus infection, unspecifiedU07.1IRCT20180302038915N1Shahid Beheshti University of Medical Sciences50